Search Results - "Von Depka, M."

Fifth Åland Island conference on von Willebrand disease by Berntorp, E., Ågren, A., Aledort, L., Blombäck, M., Cnossen, M. H., Croteau, S. E., Depka, M., Federici, A. B., Goodeve, A., Goudemand, J., Mannucci, P. M., Mourik, M., Önundarson, P. T., Rodeghiero, F., Szántó, T., Windyga, J.

“…The fifth Åland Island meeting on von Willebrand disease (VWD) was held on the Åland Islands, Finland, from 22 to 24 September 2016—90 years after the first…”
Get full text

von Willebrand's disease: a report from a meeting in the Åland islands by Berntorp, E., Peake, I., Budde, U., Laffan, M., Montgomery, R., Windyga, J., Goodeve, A., Petrini, P., von Depka, M., Miesbach, W., Lillicrap, D., Federici, A. B., Lassila, R., White, G.

“…Summary von Willebrand's disease (VWD) is probably the most common bleeding disorder, with some studies indicating that up to 1% of the population may have the…”
Get full text

Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A by Klamroth, R., Simpson, M., von Depka-Prondzinski, M., Gill, J. C., Morfini, M., Powell, J. S., Santagostino, E., Davis, J., Huth-Kühne, A., Leissinger, C., Neumeister, P., Bensen-Kennedy, D., Feussner, A., Limsakun, T., Zhou, M., Veldman, A., St. Ledger, K., Blackman, N., Pabinger, I.

“…Background rVIII‐SingleChain, a novel recombinant factor VIII (rFVIII), has been designed as a B‐domain truncated construct with covalently bonded heavy and…”
Get full text

Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction by TIEDE, A, EDER, M, VON DEPKA, M, BATTMER, K, LUTHER, S, KIEM, H-P, GANSER, A, SCHERR, M

“…Autologous transplantation of gene-modified hematopoietic stem cells may provide a therapeutic strategy for several monogeneic disorders. In previous studies,…”
Get full text

Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety by Lissitchkov, T., Hampton, K., von Depka, M., Hay, C., Rangarajan, S., Tuddenham, E., Holstein, K., Huth-Kühne, A., Pabinger, I., Knaub, S., Bichler, J., Oldenburg, J.

“…Introduction Nuwiq® [human cell line‐derived recombinant factor VIII (human‐cl rhFVIII)] is a new generation rFVIII protein, without chemical modification or…”
Get full text

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report by ASTERMARK, J., ALTISENT, C., BATOROVA, A., DINIZ, M. J., GRINGERI, A., HOLME, P. A., KARAFOULIDOU, A., LOPEZ-FERNÁNDEZ, M. F., REIPERT, B. M., ROCINO, A., SCHIAVONI, M., Von DEPKA, M., WINDYGA, J., FIJNVANDRAAT, K.

“…The development of inhibitors to the infused factor in patients with haemophilia is a serious clinical problem. Recent evidence suggests that alongside the…”
Get full text

Efficacy and safety of Nuwiq® (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures by Zozulya, N., Kessler, C. M., Klukowska, A., Depka, M., Hampton, K., Hay, C. R. M., Jansen, M., Bichler, J., Knaub, S., Rangarajan, S.

“…Introduction Haemophilia A patients are at a high risk of excess bleeding during surgeries. The aim of haemostatic therapy during the perioperative period is…”
Get full text

Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery by Solomon, C., Budde, U., Schneppenheim, S., Czaja, E., Hagl, C., Schoechl, H., von Depka, M., Rahe-Meyer, N.

“…Aortic valve (AV) defects can destroy high molecular weight multimers (HMWM) of von Willebrand factor (VWF), leading to acquired von Willebrand syndrome (aVWS)…”
Get full text

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey by Poon, M‐C., D'Oiron, R., Von Depka, M., Khair, K., Négrier, C., Karafoulidou, A., Huth‐Kuehne, A., Morfini, M.

“…Background: Antibodies to glycoprotein (GP) IIb‐IIIa and/or HLA may render platelet transfusions ineffective to stop bleeding or to cover surgery in patients…”
Get full text

Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature by Salama, A., Rieke, M., Kiesewetter, H., von Depka, M.

“…Patients with severe and refractory autoimmune thrombocytopenia (ITP) have significant morbidity and mortality rates. Currently, high-dose methylprednisolone…”
Get full text

Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery by Windyga, J, von Depka-Prondzinski, M

“…The aim of this study was to assess the efficacy of Wilate®, a new generation, plasma-derived, high-purity, double virus-inactivated von Willebrand factor…”
Get more information

Canine haemophilia A caused by a mutation leading to a stop codon by Mischke, R., Wilhelm, Ch, Czwalinna, A., Varvenne, M., Narten, K., Depka, M.

Get full text

Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors by ASTERMARK, J., MORADO, M., ROCINO, A., VAN DEN BERG, H. M., VON DEPKA, M., GRINGERI, A., MANTOVANI, L., GARRIDO, R. P., SCHIAVONI, M., VILLAR, A., WINDYGA, J.

“…The management of patients with inhibitors is an important challenge in haemophilia care. The lack of randomized controlled trials means that clinical…”
Get full text

Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety by VON DEPKA, M.

“…The options available for treating the patient with haemophilia and inhibitors undergoing surgery or with other acute bleeds include high‐dose factor VIII…”
Get full text

Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism by von Depka, Mario, Nowak-Göttl, Ulrike, Eisert, Roswith, Dieterich, Christian, Barthels, Monika, Scharrer, Inge, Ganser, Arnold, Ehrenforth, Silke

“…Elevation of serum lipoprotein (a) (Lp[a]) is a known risk factor predisposing to cardiovascular and cerebrovascular disease. However, little is known about…”
Get full text

Inhibitor Development in Patients with Hemophilia A after Continuous Infusion of FVIII Concentrates by von AUER, CH, OLDENBURG, J., von DEPKA, M., ESCURIOLA-ETTINGHAUSEN, C., KURNIK, K., LENK, H., SCHARRER, I.

“…: Continuous infusion (CI) of coagulation factor concentrates has been used since the early 1990s. Recent reports of the occurrence of an inhibitor after CI…”
Get full text

Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors by ASTERMARK, J., ROCINO, A., VON DEPKA, M., VAN DEN BERG, H. M., GRINGERI, A., MANTOVANI, L. G., MORADO, M., GARRIDO, R. P., SCHIAVONI, M., VILLAR, A., WINDYGA, J.

“…The ultimate goal of treatment for patients with inhibitory antibodies should be to permanently eradicate the inhibitor by immune tolerance induction therapy…”
Get full text

European curriculum for thrombosis and haemostasis by ASTERMARK, J., NEGRIER, C., HERMANS, C., HOLME, P. A., KLAMROTH, R., KOTSI, P., DE MOERLOOSE, P., PASI, J., ROCINO, A., VON DEPKA, M., WINDYGA, J., LUDLAM, C. A.

Get full text

Factor VIII Inhibitor–Tests Could Be Less Sensitive Than Supposed by Barthels, M., Kraus, M., Bohn, U., Liese, B., von Depka, M., Eisert, R., Ganser, A.

Get full text

Study of the Prothrombin Gene 20201 GA Variant in FV: Q506 Carriers in Relationship to the Presence or Absence of Juvenile Venous Thromboembolism by Ehrenforth, S, von Depka Prondsinski, M, Aygoren-Pursun, E, Nowak-Gottl, U, Scharrer, I, Ganser, A

“…The G20210A transition of the prothrombin gene has been identified as a common but probably mild hereditary risk factor for venous thromboembolism (VTE)…”
Get full text